None listed
Conditions
Interventions
Drug : meropnem, tazosin
Sponsors
Hallym University Medical Center
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Individuals aged 19 to 55 years as of the screening date. 2. Those without congenital or chronic diseases and showing no pathological symptoms or findings upon medical examination. 3. Individuals deemed suitable based on health screening (interview, vital signs, physical examination, hematologic tests, blood chemistry tests, urine tests, infectious serology tests, and other screening tests).
Exclusion criteria
Exclusion criteria: 1. Individuals with clinically significant diseases or past medical history in the gastrointestinal, cardiovascular, respiratory, endocrine, hepatobiliary, hematologic-oncologic, musculoskeletal, renal, neurological, psychiatric, immune, urological, ophthalmological, or otolaryngological systems, or with genetic diseases. 2. Individuals with a history of conditions that could affect the absorption, distribution, metabolism, or excretion of drugs (e.g., past history of gastrointestinal, liver, or kidney diseases). 3. Individuals with hypersensitivity to meropenem or piperacillin, including a history of such hypersensitivity. 4. Those who have participated in other clinical trials and received investigational drugs within the last six months prior to the current clinical trial. 5. Individuals testing positive for serologic tests (HBsAg, anti-HCV Ab, HIV Ag/Ab, Syphilis (RPR, VDRL, titer)). 6. Pregnant women, nursing mothers, or women who may be pregnant.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Population pharmacokinetic model | — |
Secondary
| Measure | Time frame |
|---|---|
| Pharmacokinetic parameters, covariates | — |
Countries
Korea, Republic of
Contacts
Public ContactDong Hwan Lee
Hallym University Medical Center
Outcome results
None listed